Faessel HM

No ORCID on file · 1 paper in corpus

rct 2015

Medical Castration Using the Investigational Oral GnRH Antagonist TAK-385 (Relugolix): Phase 1 Study in Healthy Males

The Journal of clinical endocrinology and metabolism ·doi:10.1210/jc.2015-2770

CONTEXT: TAK-385 is a highly selective, oral, nonpeptide GnRH antagonist being investigated as a possible prostate cancer treatment. OBJECTIVE: The objectives were to evaluate safety, tolerability, pharmacokinetics, and pharmacodynamics of…